T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Quantum-Si Incorporated
QSI
$172M
| $18.6M | ﹤0.01% |
2,359,250
+164,650
| +8% | +$1.24M |
|
1302
STRATTEC Security
STRT
$341M
| $18.5M | ﹤0.01% |
499,397
| – | – |
|
|
JNPR
1303
DELISTED
Juniper Networks
JNPR
| $18.3M | ﹤0.01% |
511,310
-23,523
| -4% | -$735K |
|
|
MRO
1304
DELISTED
Marathon Oil Corporation
MRO
| $18.1M | ﹤0.01% |
1,102,404
-7,110
| -0.6% | -$114K |
|
1305
Cloudflare
NET
$118B
| $18M | ﹤0.01% |
136,817
-659,542
| -83% | -$111M |
|
1306
Array Technologies
ARRY
$799M
| $17.8M | ﹤0.01% |
1,132,298
-1,484
| -0.1% | -$29K |
|
1307
American Airlines Group
AAL
$9.97B
| $17.7M | ﹤0.01% |
987,140
-17,929
| -2% | -$344K |
|
1308
VanEck Oil Services ETF
OIH
$1.95B
| $17.7M | ﹤0.01% |
95,873
| – | – |
|
|
EQRX
1309
DELISTED
EQRx, Inc. Common Stock
EQRX
| $17.5M | ﹤0.01% |
+2,572,573
| New | +$24.3M |
|
|
EXAI
1310
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $17.4M | ﹤0.01% |
+881,078
| New | +$18.5M |
|
1311
Lincoln National
LNC
$8.44B
| $17.4M | ﹤0.01% |
254,827
-23,343
| -8% | -$1.65M |
|
|
CVAC
1312
DELISTED
CureVac
CVAC
| $17.3M | ﹤0.01% |
504,148
+20,777
| +4% | +$836K |
|
1313
Lumen
LUMN
$6.6B
| $17.2M | ﹤0.01% |
1,374,335
-202,756
| -13% | -$2.58M |
|
1314
Haemonetics
HAE
$4.11B
| $17.2M | ﹤0.01% |
324,360
-26,905
| -8% | -$1.64M |
|
1315
Tapestry
TPR
$25.9B
| $17.2M | ﹤0.01% |
422,457
-327,763
| -44% | -$13.5M |
|
1316
Hydrofarm Holdings
HYFM
$8.58M
| $17.1M | ﹤0.01% |
60,403
+12,641
| +26% | +$4.29M |
|
1317
Arcutis Biotherapeutics
ARQT
$3.3B
| $17.1M | ﹤0.01% |
823,168
+9,474
| +1% | +$189K |
|
1318
BorgWarner
BWA
$14B
| $17.1M | ﹤0.01% |
429,839
-8,659
| -2% | -$348K |
|
1319
Everest Group
EG
$13.9B
| $17M | ﹤0.01% |
62,020
-2,264
| -4% | -$612K |
|
1320
GoDaddy
GDDY
$12.7B
| $17M | ﹤0.01% |
199,832
-8,475
| -4% | -$606K |
|
1321
Design Therapeutics
DSGN
$917M
| $16.9M | ﹤0.01% |
787,665
-661,303
| -46% | -$11.4M |
|
1322
Kyndryl
KD
$2.85B
| $16.8M | ﹤0.01% |
+928,875
| New | +$20.1M |
|
1323
Pentair
PNR
$10.5B
| $16.8M | ﹤0.01% |
229,914
-16,326
| -7% | -$1.2M |
|
1324
Organon & Co
OGN
$3.59B
| $16.4M | ﹤0.01% |
538,585
-4,991
| -0.9% | -$163K |
|
1325
Dynatrace
DT
$14.3B
| $16.3M | ﹤0.01% |
269,458
-16,584
| -6% | -$1.13M |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.